Merrimack Pharmaceuticals (MACK) : Money flow in the Merrimack Pharmaceuticals (MACK) stock was negative (1.4 million) on Wednesday, which shows that the investors used the strength in the stock price to reduce their holdings. The total traded value on upticks was $0.64 million, compared to $2.04 million on downticks. The total uptick to downtick ratio was 0.32, indicating the underlying weakness in the stock. Even in block trades, money flow was negative ($1.47 million), indicating selling on the strength. The transaction value during uptick in block trades was $0.07 million. Downtick transaction value in block trades amounted to $1.54 million, indicating persistent selling. The uptick to downtick ratio was 0.04. Merrimack Pharmaceuticals (MACK) traded $0.08 higher at $6.23 gaining 1.3% over the previous days close.
Shares of Merrimack Pharmaceuticals, Inc. rose by 22.05% in the last five trading days and 30.53% for the last 4 weeks. Merrimack Pharmaceuticals, Inc. is up 10.32% in the last 3-month period. Year-to-Date the stock performance stands at -21.52%.
Merrimack Pharmaceuticals (MACK) : Zacks Investment Research ranks Merrimack Pharmaceuticals (MACK) as 4, which is a Sell recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 3 research analysts is 2.33, which indicates as a Buy.
Merrimack Pharmaceuticals (NASDAQ:MACK): The stock opened at $6.2 and touched an intraday high of $6.295 on Wednesday. During the day, the stock corrected to an intraday low of $6.05, however, the bulls stepped in and pushed the price higher to close in the green at $6.2 with a gain of 0.81% for the day. The total traded volume for the day was 3,022,563. The stock had closed at $6.15 in the previous trading session.
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has six targeted therapeutic oncology candidates in clinical development (MM-398, MM-302, MM-121, MM-111, MM-151 and MM-141). The Companys most advanced program is its investigational agent MM-398. The Company also has multiple product candidates in preclinical development and a discovery effort advancing additional candidate medicines. The Company has an agreement to utilize its manufacturing know-how to develop, manufacture and exclusively supply bulk drug to a third party, who processes the drug into a finished product and commercializes it globally. The Company is also developing in vitro and in vivo companion diagnostics for use with each of its oncology therapeutic product candidates.